Cranbury, N.J.-based Amicus Therapeutics and the Perelman School of Medicine at the University of Pennsylvania are expanding their gene therapy collaboration.

Ovid Therapeutics reported that the Phase II STARS trial of OV101 for Angelman Syndrome showed “robust and statistically significant improvement,” but the company’s stock plunged nearly 30 percent in premarket trading.